A375 Melanoma Cell Line Resistant to LGD 1069, Thiazolidinediones, and the Combination


CU scientists have generated a human melanoma cell line that shows decreased proliferation in the presence of the RXR agonist LGD 1069, PPAR agonist rosiglitazone, and the combination. The cell line, called A375(DRO) cells, was created by slowly growing A375 melanoma cancer cells in the presence of each ligand or the combination. Importantly, the cell line has been genetically profiled and validated, and can be used in cultured cell and mouse xenograft models of melanoma. This creates a cell line for studying mechanisms of melanoma resistance to RXR and PPAR agonists.

Schweppe RE, Klopper JP, Korch C, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008;93(11):4331-41.

Klopper JP, Sharma V, Berenz A, et al. Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression. Mol Cancer. 2009;8:16.

Research Tools
For Information, Contact:
Aaron Troemner
University of Colorado
Joshua Klopper
Bryan Haugen
Disease Areas:
For inquiries, email: cuinnovations@cuanschutz.edu.     © 2024. All Rights Reserved. Powered by Inteum